In this study, we demonstrated that inhibition of FGFR signaling in FGFR2‐amplified cancers might be one of the mechanisms of antitumor activity demonstrated in preclinical and clinical evaluation of regorafenib in colorectal and gastric cancers. The gene discussed is FGFR2; the disease is cancer.